Coronavirus COVID-19 – Special Topics – Special Topics: COVID-19 Treatment and Management (G7 )
The treatment landscape for coronavirus disease 2019 (COVID-19) continues to evolve rapidly. Despite the availability of vaccines in the markets under study, research is ongoing to lower viral loads and improve outcomes. Although multiple therapies have been approved for COVID-19 in the markets under study—most notably Pfizer’s Paxlovid (ritonavir / nirmatrelvir), Gilead’s Veklury (remdesivir), and Merck’s molnupiravir—treatment guidelines in these countries and/or available clinical evidence do not always support their use. The high unmet need associated with preventing and treating this disease and its burden on healthcare systems worldwide presents significant opportunity for therapies in the pipeline. Indeed, numerous therapies with diverse mechanisms of action (MOAs) are in clinical development for COVID-19, and many of them are expected to launch in the next few years. The greater availability of treatment options will continue to transform the treatment landscape and help address the unmet need.
QUESTIONS ANSWERED
- What is the treatment algorithm for COVID-19?
- How does the treatment of COVID-19 differ based on the severity of the disease?
- What are the key areas of unmet need and opportunity in the treatment of COVID-19?
- What are the most promising therapies in development for COVID-19?
- What is the expected impact of therapies in development on the treatment of COVID-19 and the market?
GEOGRAPHIES
United States, EU5, Japan
PRIMARY RESEARCH
12 KOL interviews in February to April 2023
KEY COMPANIES COVERED
Eli Lilly, Gilead, Roche, Merck, Pfizer, Regeneron
KEY DRUGS COVERED
Paxlovid (nirmatrelvir / ritonavir), Lagevrio (molnupiravir), Xevudy (sotrovimab), Veklury (remdesivir), Kineret (anakinra), Olumiant (baricitinib), REGN-COV2 (casirivimab/imdevimab), LY-CoV555 and LY-CoV016 (bamlanivimab plus etesevimab), and other Phase III assets.
PRODUCT DESCRIPTION
Special Topics reports use primary research to assess evolving trends and market effects in dynamic disease areas. Insights from this report on COVID-19 will help developers gauge the competitiveness of their late-phase pipeline candidates and design messages to support or defend their market position.
Raina Priyadarshini, Ph.D., Lead Healthcare Research & Data Analyst, Infectious, Niche, and Rare Diseases. Dr. Priyadarshini trained as a molecular biologist; her research focused on the interplay between tumor suppressor proteins and oncoproteins. She received her doctorate from the National Institute of Immunology in New Delhi, India.